医学
PI3K/AKT/mTOR通路
长寿
养生
药理学
临床试验
疾病
生物信息学
老年学
内科学
细胞凋亡
生物
遗传学
作者
Simon C. Johnson,Matt Kaeberlein
出处
期刊:Oncotarget
[Impact Journals, LLC]
日期:2016-07-01
卷期号:7 (29): 44876-44878
被引量:50
标识
DOI:10.18632/oncotarget.10381
摘要
// Simon C. Johnson 1 and Matt Kaeberlein 2 1 Department of Genetics, Albert Einstein Medical College, New York, NY, USA 2 Department of Pathology, University of Washington, Seattle, WA, USA Correspondence to: Matt Kaeberlein, email: // Keywords : mTOR, target of rapamycin, healthspan, mitochondria, mitochondria disease Received : April 22, 2016 Accepted : June 16, 2016 Published : July 01, 2016 Abstract Experimental geroscience has identified rapamycin as a top candidate for promoting healthy aging and longevity in mammals. As multiple independent studies have successfully reproduced the lifespan and healthspan promoting effects of rapamycin, the focus has shifted to possible translational use. While a promising compound, clinical use of rapamycin is limited by concerns of side effects associated with the drug. Studies aimed at defining optimal dosage regimen, delivery route, and formulation will allow for benefits to be maximized while reducing side effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI